

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

Author

Aletaha, Daniel, Kerschbaumer, Andreas, Kastrati, Kastriot, Dejaco, Christian, Dougados, Maxime, McInnes, Iain B, Sattar, Naveed, Stamm, Tanja A, Takeuchi, Tsutomu, Trauner, Michael, van der Heijde, Desiree, Voshaar, Marieke, Winthrop, Kevin L, Ravelli, Angelo, Nash, Peter, et al.

Published

2022

Journal Title

Annals of the Rheumatic Diseases

Version

Accepted Manuscript (AM)

DOI

<https://doi.org/10.1136/ard-2022-222784>

Copyright Statement

© The Author(s) 2022. This is the author-manuscript version of this paper. It is posted here with permission of the copyright owner(s) for your personal use only. No further distribution permitted. For information about this journal please refer to the publisher's website or contact the author(s).

Downloaded from

<http://hdl.handle.net/10072/418182>

Griffith Research Online

<https://research-repository.griffith.edu.au>

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: An update

Daniel Aletaha,¹ Andreas Kerschbaumer,¹ Kastriot Kastrati,¹ Christian Dejaco,² Maxime Dougados,³ Iain McInnes,⁴ Naveed Sattar,⁵ Tanja Stamm,⁶ Tsutomu Takeuchi,⁷ Michael Trauner,⁸ Désirée van der Heijde,⁹ Marieke Voshaar,¹⁰ Kevin Winthrop,¹¹ Angelo Ravelli,¹² Neil Betteridge,¹³ Gerd R. Burmester,¹⁴ Johannes Bijlsma,¹⁵ Vivian Bykerk,¹⁶ Roberto Caporali,¹⁷ Ernest Choy,¹⁸ Catalin Codreanu,¹⁹ Bernard Combe,²⁰ Mary K. Crow,²¹ Maarten de Wit,²² Paul Emery,²³ Roy Fleischmann,²⁴ Cem Gabay,²⁵ Merete Lund Hetland,²⁶ Kimme Hyrich,²⁷ Annamaria Iagnocco,²⁸ John Isaacs,²⁹ Joel Kremer,³⁰ Xavier Mariette,³¹ Peter Merkel,³² Eduardo Mysler,³³ Peter Nash,³⁴ Michael T. Nurmohamed,³⁵ Karel Pavelka,³⁶ Gyula Poor,³⁷ Andrea Rubbert-Roth,³⁸ Hendrik Schulze-Koops,³⁹ Anja Strangfeld,⁴⁰ Yoshiya Tanaka,⁴¹ and Josef S. Smolen¹

Author affiliations

¹ Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; ² Department of Rheumatology, Hospital of Bruneck, Italy, and Department of Rheumatology and Immunology, Medical University Graz, Austria; ³ Rheumatology Department, Paris Descartes University, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; ⁴ Institute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK; ⁵ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, U.K.; ⁶ Medical University of Vienna, Center for Medical Statistics, Informatics, and Intelligent Systems, Section for Outcomes Research, Vienna, Austria; ⁷ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; ⁸ Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; ⁹ Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; ¹⁰ Department Psychology, Health and Technology, University of Twente, Twente, Netherlands; ¹¹ Oregon Health Sciences University, Portland, Oregon, USA; ¹² Università degli Studi di Genova, and IRCCS Istituto Giannina Gaslini, Genoa, Italy; ¹³ Neil Betteridge Associates, London, UK; ¹⁴ Department of Rheumatology and Clinical Immunology, Charité – University, Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, Berlin, Germany; ¹⁵ Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; ¹⁶ Department of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; ¹⁷ Department of Clinical Sciences and Community Health, University of Milan, Italy; ¹⁸ University Hospital of Wales, Rheumatology, Cardiff, UK; ¹⁹ Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania; ²⁰ Rheumatology Department, Lapeyronie Hospital, Montpellier University, UMR 5535, Montpellier, France; ²¹ Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY 10021, USA; ²² Medical Humanities, Amsterdam University Medical Centre, Amsterdam, Netherlands; NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals, NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; ²⁴ Department of Medicine, Southwestern University of Texas, Dallas, Texas, USA; ²⁵ Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland; ²⁶ Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ²⁷ Centre for Epidemiology versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK; ²⁸ Dipartimento Scienze Cliniche e Biologiche, Università degli Studi di Torino, Torino, Italy; ²⁹ Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, UK; ³⁰ Rheumatology, Albany Medical College, Albany, New York, USA; ³¹ Department of Rheumatology, INSERM UMR1184, Le Kremlin Bicêtre, France; ³² University of Pennsylvania, Philadelphia, PA, USA; ³³ Organización

Médica de Investigación, Buenos Aires, Argentina; ³⁴ School of Medicine, Griffith University, Brisbane, Queensland, Australia; ³⁵ Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Department of Rheumatology, Amsterdam, The Netherlands; ³⁶ Institute of Rheumatology and Clinic of Rheumatology, Charles University, Prague, Czech Republic; ³⁷ National Institute of Rheumatology & Physiology, Semmelweis University, Budapest, Hungary; ³⁸ Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Switzerland; ³⁹ Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians University Munich, Munich, Germany; ⁴⁰ Programme Area Epidemiology, Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany; ⁴¹ First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.

Abstract

Background. Targeting IL-6 has become a major therapeutic strategy in treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6R α antibodies, or by inhibiting the IL-6 cytokine directly. This is an update of a previous consensus document aiming to inform on the interference with the IL-6 pathway based on evidence and expert opinion.

Methods. A systematic literature search was performed that focused on IL6-pathway inhibitors in rheumatoid arthritis and other diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document.

Results. The consensus covers relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu disease, adult-onset Still's disease, Castleman's disease, CAR-T-cell induced cytokine release syndrome, neuromyelitis optica spectrum disorder. Furthermore they cover aspects of pre-treatment screening, safety, contraindications, and monitoring.

Conclusions. The document provides a comprehensive consensus on IL-6 pathway inhibitors to inform patients, administrators and payers.

Introduction

When looking back at the first two decades of the new millennium, patients with rheumatoid arthritis (RA) and rheumatologists can be very pleased with the advances made since the year 2000. While at the end of the preceding century only conventional synthetic (cs) disease modifying antirheumatic drugs (DMARDs) were available and RA patients often could not attain optimal disease control, the last 20 years have allowed five tumour necrosis factor (TNF)-inhibitors (i), two interleukin (IL)-6 receptor (R) blockers, one co-stimulation inhibitor and an antibody to the CD20 surface antigen of B-lymphocytes to become approved and successfully applied, in addition to the more weakly efficacious IL-1 receptor antagonist.¹ In addition to these biological (b) DMARDs, most recently, five Janus kinase (JAK) inhibitors have been introduced into the armamentarium for combatting RA, targeted synthetic (ts) DMARDs that can be taken orally.²

In addition to all these medicines, strategic trials have been performed³⁻⁹ which not only inspired the development of treat-to-target recommendations,¹⁰ but also informed management recommendations of major international organisations.¹¹⁻¹³ These management recommendations provide important general guidance to rheumatologists, patients and other stakeholders on what is regarded to be an optimal treatment approach based on evidence and expert opinion. However, since these recommendations have to cover the totality of the therapeutic area, they do not always dwell deeply in specific aspects of individual drugs. Therefore additional consensus statements on the use of individual agents or classes of agents have been developed by various expert groups over the years.^{2;14-16} One of these consensus statements addressed inhibition of the IL-6 receptor, dealing in detail with all important aspects of efficacy and safety in patients with RA.¹⁷

Importantly, however, rheumatology has spearheaded therapeutic developments in other areas and, therefore, the indications for agents originally developed for RA have expanded over the years. Consequently, some consensus statements also embraced diseases beyond RA and beyond rheumatology.^{2;15}

Many of the therapeutics successfully applied in patients with inflammatory rheumatic diseases target proinflammatory cytokines, their receptors or their signal transduction. Among these cytokines IL-6 stands out by virtue of its very high serum concentration and its pivotal role in the induction of the acute phase response.^{18;19} IL-6 is a cytokine with multiple effects that is produced by most cell types.²⁰ Due to its pleiotropic nature IL-6 is involved in many fundamental processes of cell growth and cell activation, such as embryonic development, hematopoiesis, bone metabolism, immune responses and inflammation.²¹ Immunologically, IL-6 is an important factor regulating B-cell growth, maturation and activation (previously even called B-cell stimulating factor), and it is also

importantly involved in the generation of T helper (h) 17 cells which produce IL-17.^{22;23} In the context of rheumatoid arthritis and other immune mediated inflammatory diseases (IMIDs), it is pivotal in the generation of the overall inflammatory response, joint damage based on its capacity to activate matrix metalloproteinases and osteoclasts,^{24;25} aside from being the major driver of acute phase reactant production.²⁶

IL-6 is not only the most abundant cytokine in the circulation, it also uses a variety of means to bind to and activate target cells either directly or indirectly. IL-6 always binds to its cognate receptor IL-6R α , but this receptor is located either on the cell surface or cleaved into a soluble form. The IL-6R α chain, even if membrane bound, has no intracellular signaling moiety and requires a co-receptor, gp130 or IL-6R β , to transmit information to the nucleus. To this end, Janus kinases (JAKs), a series of non-receptor tyrosine kinases, are activated which phosphorylate signal transducer and activator of transcription proteins (STATs), the respective transcription factors. Signaling ensues after engagement of two IL-6 ligand molecules with two IL-6R α molecules and two gp130 moieties, forming a hexameric structure on the cell surface.²⁷ Interestingly, many cells express gp130 without the IL-6R α chains. However, soluble IL-6R (sIL-6R) is present at high blood levels, can bind IL-6 in the circulation, and then interact with membrane gp130 on various cell populations, a process called transsignaling (as opposed to classical signaling). More recently, a third signaling mechanism has been recognized, namely trans-presentation, where IL-6R α present on a cell surface, after having bound IL-6, can interact with a gp130 molecule expressed on another cell.^{21;28}

Targeting IL-6 has become a major therapeutic opportunity to combat inflammation. Generally, one can interfere with IL-6 directly or prevent its binding to the specific receptor using anti-IL-6R α antibodies. While , already in very early days xenogeneic monoclonal antibodies against IL-6 have been tested,²⁹ humanized and human anti-IL-6 molecules, such as sirukumab, olekizumab or clazakizumab, have been developed and tested in various clinical trials since then, but none has been approved hitherto. In contrast, a humanized monoclonal antibody targeting IL-6R α , tocilizumab, has been licensed more than a decade ago for RA and has been used successfully in this and other indications. More recently, a human antibody against IL-6R α , sarilumab, has also been approved for RA, a further expansion of the specific approach to inhibit IL-6 mediated inflammation. A third possibility to interfere with IL-6 effects is by inactivating the “IL-6 - IL-6R α complex” with a sgp130 Fc receptor construct like Olamkicept. However, this molecule is in early phase development and likely would also affect other members of the IL-6 family. Interference with IL-6 signal transduction can also be accomplished using JAK inhibitors; however, their effect is not confined to just IL-6, as many more cytokines and growth factors use the JAK-STAT pathway, as described in a recent consensus statement on the use of JAK inhibitors.²

At the time of the first consensus statement on IL-6 and IL-6R α inhibition almost one decade ago, the only approved molecule targeting this pathway was tocilizumab and the approved indications were RA, systemic juvenile idiopathic arthritis (sJIA)¹⁷ and, in Japan, Castleman's disease. Since then, several IL-6 directed antibodies underwent phase III trials; tocilizumab was licensed for many more indications; and sarilumab was approved as the second anti-IL-6R α for RA and several head-to-head trials employing anti-IL-6R α antibodies have been performed. In addition, much more safety information is available today, including information from registries, since the previous consensus statement.

For all these reasons it was deemed timely to revisit the previous consensus statement and to advance it to include the most recent insights into indications, efficacy and safety by assessing the evidence accrued since the previous version of the statement, discussing this evidence among experts in IMIDs as well as patient representatives and developing an updated consensus document to reflect the current state of the art.

MOLECULAR ASPECTS OF IL-6R and IL-6 INHIBITION

Before dwelling on the updated consensus statement, a brief look at the molecular aspects of blocking the IL-6 receptor or its ligand is warranted. The monoclonal anti-IL-6R antibodies tocilizumab, sarilumab and satralizumab all target Domain 2 of the IL-6R molecule which is the main point of engagement with its ligand IL-6.³⁰ Thus, these monoclonal antibodies prevent the binding of IL-6 to its soluble and cell surface receptors; as a consequence of this inhibition, IL-6 levels increase in the circulation (without leading to inflammatory responses). ALX-0061, a nanobody, targets the same site but has not yet undergone clinical studies in detail.^{30;31} However, the IL-6R also has other domains, including Domain 3 which is the site of its interaction with gp130; this region can be targeted by the mAb NI-1201 which also has of yet not undergone clinical trials.³²

The IL-6 cytokine has several functional regions.³³ A Site 1 is the main binding site to the cognate IL-6R and is inhibited, among others, by siltuximab, sirukumab (the human version of siltuximab³⁴) and clazakizumab.³⁰ Site 3 of IL-6, however, is the binding region of the IL-6R-IL-6 complex to gp130 and is blocked by olokizumab. An antibody to site 2, EBI-029,³⁰ which also interacts with gp130, has not yet been studied for human disease but is available for experimental work.³⁵

Thus, there is an inherent complexity not only regarding the potential interactions between IL-6 and the various forms of its receptors, but agents blocking the ligand, or the receptor can interact with different sites of these molecules. This complexity regarding therapeutic approaches to interfere with the IL-6 pathway is further enhanced by our ability to inhibit signal transduction with JAK-

inhibitors, but these compounds will not be addressed in the present consensus statement; rather, the focus here will be solely on the respective bDMARDs.

METHODS

Two convenors (DA and JS) brought a Task Force (TF) together based on the expertise regarding the specific task to develop an update of the Consensus Statement on the use of IL-6 inhibition. The work of the TF adhered to the EULAR standard operating procedures for recommendations.³⁶ In contrast to the previous version, due to the expansion of indications, this task force had to include experts from areas beyond adult rheumatology. First, a Steering Committee (SC) was formed which consisted of a patient representative (MV), a health professional (TS), a gastroenterologist (MT), a cardiologist and metabolism expert (NS), an infectious disease specialist (KW), a pediatric rheumatologist (AR), nine adult rheumatologists with various scientific focusses from basic to clinical research, a fellow (KK) and a methodologist (AK). The SC members came from several European Countries, Japan (TT) and USA (KW). The SC was charged to first develop questions for the systematic literature research (SLR). Once the fellow had performed the SLR under the supervision of the methodologist, and with oversight from the convenors, the SC critically discussed the SLR and developed a proposal for the updated bullet points of the consensus statement.

The TF included all SC members plus two additional patient representatives (NB, MdW), seven additional rheumatologists from North America, Japan (YT) and Australia (PN), and 14 additional rheumatologists from several European countries. The special research focus of several of the rheumatologists span from vasculitis to systemic lupus erythematosus and included colleagues with a vast experience in leading registries and cardiovascular medicine. At the TF meeting the fellow presented the SLR results and the convenors the proposal for the individual statements as developed by the SC. These proposals were further discussed, reformulated as needed and underwent online voting. All items received an adjudication of the Level of Evidence (LoE) and Strength of Recommendation (SoR) according to the Oxford Evidence Based Medicine approach.³⁷

As suggested in the EULAR standard operating procedure, the first vote had to arrive at a 75% majority for acceptance; if further discussions were needed, a next proposal of the respective bullet point had to reach a two thirds majority and, if still needed, the final wording had to be approved by more than 50% of the TF members. Due to the COVID-19 pandemic, all discussions and voting took place remotely. Anonymity of the voting process was ensured during the TF meeting. Notes captured the contents of the discussions and the reasoning behind each decision. These discussions are represented in the manuscript as comments accompanying each individual items.

After the meeting, the TF members received all statements in a table format and submitted their level of agreement with each of the items by assigning a vote between 0 and 10 (0 meaning no agreement at all and 10 full agreement); the mean of these responses was calculated as the mean level of agreement (LoA; Table 2).

The details of the SLR are published separately.³⁸ Of note, drugs that had not yet undergone regulatory assessment or formal approval, but for which evidence from clinical trials was available, were part of the SLR and could be considered in the recommendations with the respective caveats.

The individual statements are presented in the wording of the final vote (Table 2). The results of the respective last ballot are presented as percentage of voting members present in the virtual room (Table 2).

The convenors drafted the initial version of the manuscript with the help of the methodologist and the fellow. This draft was sent to all task force members for their comments. All comments were considered for the next version of the paper and all authors provided their final approval prior to submission of the manuscript.

CONSENSUS STATEMENT ON THE USE OF IL-6-PATHWAY INHIBITORS

The consensus statement on the use of IL-6 pathway inhibition covering indications, management, safety, and other aspects, are shown in Table 1. In the following, we will address some details of the task force's deliberations and conclusions.

Indications, considerations and screening for treatment initiation, dosing

Indication

ADULT RA

In line with the current licensed indication in Europe, sarilumab and tocilizumab may be used in adult patients with active RA, normally with at least moderate disease activity according to a validated composite measure, who have had an inadequate response to, or intolerance of at least one DMARD. EULAR recommends use of csDMARDs in combination with short-term glucocorticoids before deciding that the csDMARD treatment is insufficiently effective.¹²

Sarilumab and tocilizumab fulfilled the requirements for the above indication as a consequence of the results of several clinical trials (Level 1a, Grade A). The data for tocilizumab were detailed in the

previous version of this consensus statement, however, further studies were performed since then and are addressed in the SLR as detailed in the respective document.³⁸ Superiority of tocilizumab and sarilumab monotherapy^{39;40} over monotherapy of TNF-inhibitors as well as similarity of all bDMARD mechanisms in combination with MTX were reported in SLRs for the EULAR management recommendations for RA.^{41;42} This latter finding was recently confirmed in a head-to-head trial in which three bDMARDs, tocilizumab, certolizumab pegol and abatacept, when combined with MTX and glucocorticoids, showed similar efficacy.⁴³ This was further supported by a recent study comparing tocilizumab with rituximab.⁴⁴ Registry data reveal similar efficacy among bDMARDs.⁴⁵

Outside the USA, the approved dose of TCZ should be 162mg sc weekly and the iv dose is 8mg/kg every 4 weeks. In the USA, the recommended starting dose is 162mg sc every other week or 4mg/kg iv every 4 weeks to be followed by 162mg sc weekly or 8mg/kg iv with insufficient response to the lower dose. The reasoning behind the 162 mg every other week and 4mg/kg dosing was based on the FDA's perceived safety concerns despite being much less efficacious in clinical trials; the lower dose has also been associated with more hypersensitivity reactions. The approved dose of SAR is 200mg sc, every 2 weeks. Dose reductions (interval increase for TCZ sc; reduction to 4mg/kg for TC iv; or decrease to 150mg SAR sc every 2 weeks) should be considered in case of serious infections or persistent cytopenia. Interval increases or dose decreases should be considered when patients reach stable ACR-EULAR Boolean or index-based remission, in line with the respective management recommendations. Combination with MTX is the treatment of choice and more efficacious than monotherapy with both SAR and TCZ. Details on dose tapering and combination are provided in the SLR paper.

With respect to efficacy after failure of TNF-inhibitors, some open label clinical trials suggested that non-TNF-inhibitors including tocilizumab were more efficacious than a second TNF-inhibitor,⁴⁶ but the EULAR SLRs did not identify convincing high-level evidence to suggest any bDMARDs over another after insufficient response to TNF-blockers. The efficacy of TCZ is higher when combined with MTX compared with TCZ monotherapy according to several studies.⁴⁷⁻⁴⁹ While other studies suggest non-inferiority of withdrawing versus continuing MTX in combination with tocilizumab, the evidence favors the demonstration of better efficacy for tocilizumab combination than monotherapy. In addition, it is difficult to understand why MTX should be withdrawn if it is well tolerated and leads to better efficacy, as shown in all these studies. Nevertheless, if there is a strong patient preference or if all csDMARDs are contraindicated, monotherapy of monoclonal antibodies against the IL-6R have an advantage over other bDMARDs.^{12;50}

One question raised in the research agenda from the previous edition of the consensus addressed the use and efficacy of JAK inhibitors after IL-6R blockade has failed. This question is now answered, since there was no difference in efficacy if patients failed TNF inhibitors or tocilizumab.⁵¹

Response rates according to the American College of Rheumatology (ACR) improvement criteria⁵² as observed in phase III clinical trials, have consistently shown superiority compared with control arms. A significant decrease in the disease activity score using 28 joint counts (DAS28) and high proportions of European League Against Rheumatism (EULAR) moderate and good response as well as DAS28 remission (DAS28<2.6) rates were observed. However, interpretation of these data is difficult because of the high weight of the acute phase reactant (APR) component in the DAS28 formula^{53;54} and the prominent effect of IL-6 inhibition on the hepatic APR production, which can lead to exaggerated improvement of response rates if this measure is employed. Nevertheless, the pre-eminent requirement for improvement in both swollen and tender joints to fulfill ACR improvement criteria and the published clinical trial data showing a decrease in disease activity across all variables studied as well as functional improvement and structural effects, provided solid evidence that tocilizumab is an effective bDMARD. Indeed, when looking at the clinical disease activity index (CDAI), a score that does not comprise an APR in its formula,⁵⁵ sarilumab and TCZ were also significantly more efficacious compared to the respective comparators, placebo or anti-TNF as a monotherapy.^{39;40;48} Of note, as mentioned previously, in combination with MTX, the efficacy of anti-IL-6R agents appears to be of similar magnitude as that of TNF-inhibitors, abatacept and rituximab^{1;41-43} (level 1a, grade A).

OTHER INDICATIONS

IL-6R and IL-6 blockade is also approved for a variety of other diseases. The various studies are detailed in the SLR paper³⁸ and will not be broadly addressed here.

Polyarticular-course idiopathic juvenile arthritis (pcJIA; level 1b, Grade A), systemic JIA (sJIA; level 1b, Grade A) and adult-onset Still's disease (AoSD; level 1b, Grade A)

As for the other indications, the approval for pcJIA, sJIA and AoSD is based on randomized controlled clinical trial data. However, the number of trials available are fewer than those for RA.

For children above 2 years with active *pcJIA* non-responsive to MTX, TCZ is approved at an iv dose of 8mg/kg every 4 weeks at a weight of 30kg or more and 10mg/kg every 4 weeks at a weight of <30kg. These data are based on the CHERISH trial.^{56;57} The s.c. dosing is 162mg every 2 weeks for children ≥30kg and every 3 weeks for those <30kg.⁵⁸ It is recommended to combine TCZ with MTX (whether

seropositive or seronegative), unless not tolerated. It is expected that sarilumab will show similar efficacy as tocilizumab in pcJIA, but the trial (NCT02991469) has not yet been completed.

In *sJIA* the recommended iv dose is 8mg/kg every 2 weeks at a weight of 30kg or more and 12mg/kg every 4 weeks at a weight of <30kg.^{59;60} The s.c. dose is 162mg weekly or every other week for children ≥30kg and <30kg, respectively.⁵⁸

For *AoSD* with insufficient response to glucocorticoids, tocilizumab is approved in Japan at an iv dose of 8mg/kg every 2 weeks with a possibility of weekly infusions if the response is inadequate.^{61;62}

Giant cell arteritis (GCA; level 1b, Grade A), and Takayasu arteritis (TAK; level 2a, Grade B)

A large study in GCA patients (GiACTA) was successful and was the basis for approval of TCZ for patients with new onset or relapsing disease, particularly those at risk of glucocorticoid-related adverse events.⁶³ The approved dose is 162mg s.c. weekly to be started in combination with glucocorticoids but alongside subsequent glucocorticoid tapering. In addition to the pivotal clinical trial, many case series and one other but small randomized controlled trial (RCT) have been published.⁶⁴

IL-6R inhibition with TCZ is also approved for glucocorticoid resistant TAK in Japan, although the primary endpoint of the confirmatory trial was missed.⁶⁵ A dose of 162mg weekly s.c. is recommended; similar to GCA, it should be started in combination with glucocorticoids but associated with subsequent glucocorticoid tapering.

CAR-T cell induced cytokine release syndrome (CART-CRS; level 2c, Grade B)

Treatment with chimeric antigen receptor T cells (CAR-T cells), approved for acute lymphoblastic leukemia and various lymphomas, is associated with a life-threatening cytokine release syndrome. IL-6R inhibition dramatically interferes with the development of this syndrome⁶⁶ and has been approved for patients 2 years or older with this indication at a dose of 8mg/kg (iv; 12mg/kg if weight is <30kg).⁶⁷

Castleman's disease (CD, level 2b/1b, Grade B)

Idiopathic multicentric CD (MCD) is a lymphoproliferative disorder characterized by dramatic overproduction of IL-6. For many years it has been known that IL-6R inhibition can be successfully used to interfere with the disease.⁶⁸ TCZ is approved for the treatment of MCD in Japan at an iv dose of 8mg/kg every 2 weeks or 162mg sc weekly. The approval was based on the results of an open-label prospective study. IL-6 blockade with siltuximab is efficacious in treating MCD, as demonstrated

in a RCT,^{69;70} and this therapy has been approved in Europe, US and other areas at an iv dose of 11mg/kg every 3 weeks.

Neuromyelitis optica spectrum disorder (NMOSD; level 1b, Grade A)

NMOSD is an autoimmune demyelinating disease distinct from multiple sclerosis. Inflammatory lesions are located in the optic nerve, brainstem, and cerebrum, but can also be found in the spinal cord. Motor and sensory impairment, bladder dysfunction and vision loss are some of the symptoms of this disease.⁷¹ In contrast to IL-6 pathway inhibition, the various therapies for multiple sclerosis are not effective in NMOSD.^{72;73} Indeed, satralizumab, a humanised anti-IL-6R antibody, has proven efficacious in this disease and has been approved in the USA and Japan at a SC dose of 120 mg at weeks 0, 2, and 4 and every 4 weeks thereafter with or without immunosuppressive agents.

Further potential indications

IL-6R inhibition has been studied in polymyalgia rheumatic (PMR). Case series and a subgroup analysis of GCA patients with PMR symptoms suggested efficacy^{74;75} and a recent phase II/III RCT provided clarity regarding good efficacy and acceptable safety in PMR(REF).

Tocilizumab was also studied in systemic sclerosis and current data suggest an effect on lung function but not skin changes;^{76;77} it has recently (after the consensus meeting) been approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease.

Many other diseases have been studied. IL-6R or IL-6 inhibition clearly failed to show efficacy in axial spondyloarthritis⁷⁸⁻⁸⁰ and psoriatic arthritis, but its role in systemic lupus erythematosus is still unclear, though phase I/II studies did not provide overwhelmingly convincing results^{81;82}. All these trials are mentioned in the SLR publication and will not be further addressed here.³⁸

Finally, given that severe COVID-19 is associated with hyperinflammation⁸³ and IL-6R blockade with tocilizumab and sarilumab has a significant beneficial effect in critically sick patients in retrospectively and prospectively evaluated patients,⁸⁴⁻⁸⁷ SARS-CoV-2 infection with severe pulmonary manifestations may be yet another indication, and indeed, after the meeting, on July 6, 2021, the World Health Organization recommended the use of IL-6 receptor blockade for severely ill COVID-19 patients.⁸⁸ The US FDA (emergency authorization) and EMA have meanwhile approved IL-6R blockade for this indication.^{89;90}

DISEASE MANAGEMENT AND OUTCOME (with a focus on RA)

Disease management in the context of IL-6 pathway inhibition concerns involves several considerations. First the right indication must be present. Then appropriate precautions need to be taken to ensure optimal patient safety. Finally, monitoring and the choice and performance of outcome measures need to be considered. The indications and precautions are discussed in sections above and below. In addition, however, it would be desirable to have biomarkers available that may predict efficacy and/or safety issues. Moreover, clinical assessment also requires specific considerations when applying IL-6 pathway blockers. The available evidence for predictive biomarkers and outcome measures will be summarized in the following.

Current evidence suggest association of some biomarkers with response: these include low pre-treatment IL-6 levels that are predictive of response to tocilizumab or to sustained effectiveness after its cessation.^{91,92} High pre-treatment C-reactive protein level may serve as an indicator of better response compared with low baseline CRP-levels, contrasting other drugs.⁹³ Interestingly, the data on predictive CRP-levels for a good tocilizumab response⁹³ find a correlate in predictive IL-6 levels for a good sarilumab response.⁹⁴ Data on obesity and lower treatment response are more controversial.⁹⁵⁻⁹⁷

Disease activity assessment should be typically done using composite measures of disease activity, such as DAS, DAS28, SDAI and/or CDAI. CDAI is the preferred metric, as the others include a measure of the APR which is problematic given the effect of IL-6 inhibition on CRP levels and ESR. An improvement of APR may be profound despite lack of clinical improvement confounding the interpretation of the response. One should be vigilant for the timely detection of serious infection, as signs and symptoms of acute inflammation may be lessened during treatment with IL-6 pathway inhibitors; patients may be at risk of undetected infection, because of the effects of IL-6R inhibitors on CRP, neutrophils as well as signs and symptoms of infection. This is particularly relevant in younger children with sJIA or pJIA who may be less able to communicate their symptoms. In summary, it is recommended to either thoroughly and cautiously evaluate patients on these treatments, and alternatively use the CDAI (level 5, grade D).

In line with prior recommendations, disease activity assessment should be done every 3 months, aiming at a significant improvement (>50%) within 3 months and attaining low disease activity (CDAI≤10, SDAI≤11, DAS28<3.2) or remission (using ACR-EULAR remission criteria⁹⁸) within 6 months (level 5, grade D).¹² If a patient does not achieve low disease activity within 6 months at an adequate dose (or does not experience a significant improvement of disease activity within 3 months) another treatment option should be considered (level 5, grade D).

With respect to patient adherence, one RA study identified low initial CRP, high HAQ, high fatigue and pain, smoking and prior exposure to bDMARD as predictors of TCZ discontinuation.⁹⁹ Persistence with tocilizumab was not different in combination with methotrexate than as a monotherapy¹⁰⁰ and tocilizumab treated patients exhibited a similar response as those receiving other bDMARDs, among patients with RA who had previously received ≥ 1 bDMARD.¹⁰¹ As expected, patients who were biologic naive showed numerically better improvements in all patient reported outcomes (pain, fatigue, patients global assessment of disease activity, morning stiffness) than patients who were already exposed to bDMARDs. Patients treated with tocilizumab or sarilumab monotherapy reported greater improvements across multiple PROs compared to csDMARD or TNFi (adalimumab) monotherapy in clinical trials.¹⁰²⁻¹⁰⁴ With respect to the administration, one small observational study showed that patients with JIA switching from IV to SC route experienced better efficacy and quality of life, school success, and reduced school absenteeism.¹⁰⁵

A final aspect relates to the use of glucocorticoids when IL-6 pathway blockade is applied. Glucocorticoids, especially if used at doses >5 mg prednisone equivalent per day or for prolonged periods of time, are associated with significant adverse events, not the least of which is cardiovascular adverse events.^{106;107} However, it has been observed that many RA patients in registries or who enter clinical trials continue their glucocorticoid therapy at doses of 5mg daily or higher. In a recent study, among RA patients on TCZ who either continued or tapered glucocorticoids one third experienced an increase of disease activity upon withdrawal of glucocorticoids, but in two thirds no flares were observed.¹⁰⁸ Similarly, the importance of using IL-6R inhibition in patients with other diseases, such as GCA, relates to the need of prolonged glucocorticoid use and consequent adverse events, especially in the elderly population of GCA patients,¹⁰⁹ allowing for the reduction and possible discontinuation of glucocorticoids more rapidly.

COST EFFECTIVENESS

The evaluation of cost-effectiveness of compounds has become a moving target, as costs of expensive drugs change in the competitive field as soon as biosimilars become available. Based on an analysis of MarketScan/Medicare datasets, tocilizumab had the lowest real-world healthcare costs, compared to originator infliximab and abatacept.¹¹⁰ Tocilizumab plus methotrexate showed to be a cost-effective initial biologic treatment for patients with moderate-to-severe RA after failure of one or more csDMARDs,¹¹¹ while first line combination therapy of tocilizumab plus methotrexate was not superior to a step-up strategy from methotrexate using a T2T approach over 2 to 5 years in early RA.¹¹² Using data from the ADACTA trial, costs to achieve clinical response were lower in patients

with RA who received tocilizumab monotherapy than in those who received branded adalimumab monotherapy;¹⁰¹ In addition, hospitalization costs were lower in patients who received tocilizumab than in those who received adalimumab. In a cost-effectiveness analysis of patients with insufficient response to csDMARDs reported by the manufacturer, sarilumab 200mg plus methotrexate outperformed other bDMARD and tsDMARD treatments (adalimumab, certolizumab, golimumab and tofacitinib) by resulting in lower costs and greater health benefit.¹¹³ However, cost-effectiveness studies have mostly been performed among RA patients and more data need to be assembled in other indications. Moreover, comparisons between IL-6R blockers and other bDMARDs were made at a time before biosimilars became available and, therefore, these data are not pertinent for all agents for whom bsDMARDs have been approved. On the other hand, once biosimilars of the first IL-6R inhibitor, tocilizumab, will become available, they may again provide valuable information.

PRE-TREATMENT SCREENING (Level 5, Grade D) and CONTRAINDICATIONS (Level 5, Grade D)

As before all newly introduced therapies, several investigations need to be undertaken to mitigate and minimize the risk of adverse effects. This includes a history and physical examination to evaluate the presence of contraindications or settings where the compound needs to be used cautiously. According to the summary of product characteristics true contraindications are limited to hypersensitivity to the active substance or to any of the excipients, as well as active, severe infections, or a history of recurring or chronic infections; predisposing underlying conditions, such as diverticulitis and diabetes need to be considered.¹¹⁴ Nevertheless, there exist several special warnings and clinical scenarios that are relevant for consideration before initiating therapy with an inhibitor of IL-6R: it is therefore advised to screen for latent tuberculosis, hepatitis B/C, severe hepatic disease, a previous history of intestinal ulceration or diverticulitis (or symptoms suggestive of such), altered blood cell counts, severe lipid disorder or a history of malignancies.

Vaccinations should be performed in accordance with respective recommendations ideally before the administration of TCZ; live vaccines should be avoided during TCZ therapy. Several recent open label vaccination studies indicated that that IL-6R inhibition with tocilizumab did not hamper antibody response to influenza, pneumococcal vaccine, or tetanus toxoid vaccine.¹¹⁵⁻¹¹⁸ EULAR strongly recommends the use of COVID-19 vaccination and except for rituximab there is no indication that biologic agents hamper the development of an immune response to SARS-CoV-2 vaccines.¹¹⁹⁻¹²¹ Concomitant methotrexate had a negative effect on antibody response when tocilizumab was used.¹¹⁶ The efficacy of influenza vaccination did not differ significantly between the tocilizumab treated sJIA patients and healthy controls.¹²²

SAFETY (Level 2b, Grade B)

Safety issues are the major concern with any type of new treatment modality, and this is linked to a lack of sufficient power to detect all relevant signals from short-term RCTs, and the usually prolonged absence of long-term data from extension studies or real-life evidence from registries or market data. For IL-6 Inhibition with tocilizumab all these sources exist and evidence-based consensus conclusion are presented here.

Infections. Infectious adverse events of major interest include severe infections, opportunistic infections, and infections of special interest (e.g., hepatitis, herpes virus infection). TCZ showed an increased risk for septicemia, diverticulitis, pneumonia/upper respiratory tract infections, and skin infections, with statistical significance in individual studies comparing these rates to TNF-inhibitors, but without consistent replication across those studies, with significant variability.¹²³⁻¹²⁶ Overall, serious infectious AE and the risk of hospitalisation for infectious AE was comparable to other biologics. Similarly, IL-6 inhibition with TCZ did not show an increased risk for herpes zoster, opportunistic infections or tuberculosis in comparison to TNF-inhibition or abatacept.^{123;127;128} No new data exist to modify the conclusion about Hepatitis B/C and the use of TCZ, where it should either be avoided or antiviral treatment should be used. In post-marketing data from Japanese patients who had a history of hepatitis B/C virus or who were carriers, none of these patients experienced virus reactivation (with or without hepatitis) after exposure to TCZ.¹²⁹ When treatment with IL6-inhibitors is considered, clinicians should be aware that the diagnosis of infectious events may be delayed secondary to the absence of elevations of acute phase response markers.

Malignancies. For malignancies sources of new data on IL-6R inhibition come from registries and claims databases which indicate no increased risk for overall cancer incidence, or specific cancer types. In general, with the notable exception of non-melanoma skin cancer, compared to csDMARD treated patients in the general RA population, TCZ was associated with a reduced hazard ratio of developing a malignancy.^{130;131}

Gastrointestinal and hepatic events. The increased risk for gastro-intestinal perforations requiring hospitalization, and particularly lower GI tract perforations with TZC treatment compared to other bDMARDs has been confirmed in recent studies. Therefore continuous risk mitigation approaches are required, including an evaluation for risk factors such as a history of diverticulitis or GI ulcers, older age, glucocorticoid or NSAID use. Transaminase elevations >1-3x ULN occurred in more than half of patients treated with TCZ in one large pooled RCT cohort. They were more frequently observed when

combined with MTX than as a monotherapy; rates of severe hepatic AEs occurred in 0.04/100 patient years.¹³²

Lipid levels (Level 1b, Grade A). The MEASURE trial investigated the effects of TCZ on lipid outcomes in comparison to placebo in an MTX-IR population.¹³³ It was found that the median total-cholesterol, low-density lipoprotein-cholesterol (LDL-C) and triglyceride levels increased in TCZ in comparison to PBO. Similar findings were made in a comparison of TCZ to ADA, with LDL-C and HDL-C both increased significantly more with TCZ than with ADA.¹³⁴ However, TCZ likely favourably modified the lipid profile towards an anti-inflammatory composition.

Haematologic Events. Effective treatment of chronic inflammatory systemic disease is expected to improve anemia of chronic disease; this effect may be blunted by negative or adverse effects on the red blood cell count. IL-6 inhibition with TCZ showed significant increase in hemoglobin and hematocrit levels in anaemic and non-anaemic patients with rheumatoid arthritis, compared to other biologic and nonbiologic DMARDs.¹³⁵ In a pooled analysis of phase III and IV trials of TCZ, more TCZ- than placebo-treated patients were observed to have grade 1/2 or 3/4 neutropenia.¹³⁶ Rates of serious infections were similar in patients with normal neutrophil counts, and those with grade 1/2 or grade 3/4 neutropenia. Generally, neutrophil counts decreased through week 6 from baseline and remained stable thereafter. Tocilizumab can also induce macrophage activation syndrome (MAS), especially in children¹³⁷). While MAS has also been reported with other IL-6 blocking agents,¹³⁸ it is of concern primarily with IL-6R blockade and requires rapid recognition and appropriate therapeutic interventions.

Cardiovascular safety and venous thromboembolism (including pulmonary embolism; level 1b, Grade A). Evaluation of the existing evidence would suggest that IL-6 inhibition with tocilizumab is not associated with an increased risk of cardiovascular events compared to other DMARDs, particularly TNF-inhibitors, abatacept, or rituximab in the general RA population. The ENTRACTE trial compared tocilizumab to etanercept in a dedicated trial designed to rule out a higher risk for cardiovascular events with tocilizumab versus etanercept.¹³⁹ The results showed that cardiovascular risk is not increased with tocilizumab but also that there were no differences in deep vein thrombosis (DVT) or pulmonary embolism (PE) (events per 100py: 0.2/0.06 for TCZ; 0.3/0.2 for ETN). Additional analyses based on claims databases also concluded that there was no increase in MACE in TCZ patients.¹⁴⁰⁻¹⁴²

Other adverse events of interest. IL-6 inhibition does not appear to facilitate worsening of diabetes.¹⁴³ In a study of sarilumab, an even greater reduction in HbA1c was seen compared to PBO or ADA at week 24 in patients with baseline HbA1c \geq 7%.¹⁴⁴ Similarly, TCZ demonstrated a stable safety and tolerability

profile in patients with RA and renal insufficiency, regardless of MTX use,¹⁴⁵ and may thus be a treatment option for patients with RA and concomitant renal insufficiency. Recent observational studies of TCZ did not detect an increased risk of interstitial lung disease,¹⁴⁶ demyelinating disease or idiopathic facial nerve palsy;¹⁴⁷ on the contrary, IL-6R inhibition was shown to be efficacious in one open-label trial in demyelinating disease.¹⁴⁸ There was no difference in the incidence of osteoporotic fractures in patients treated with TCZ as compared to those receiving TNF-inhibitors;¹⁴⁹ TCZ has been found to positively affect bone-turnover and improve bone mineral density in ACPA positive patients.^{150;151}

Safety considerations with other biological IL-6 pathway inhibitors. Sarilumab and sirukumab are the two other IL-6 pathway inhibitors with the largest body of data. Sarilumab, an IL-6R-inhibitor, is approved for RA with a based on several phase-3 clinical trials and extension data. The data from these trials suggest that its safety and tolerability profiles is consistent across studies and comparable with tocilizumab, with no new safety signals emerging.¹⁵² This is different from sirukumab, a direct inhibitor of the IL-6 cytokine, which was not approved by the FDA in 2017 because of a numerically higher rate in mortality among patients treated with sirukumab compared to controls.^{153;154} Cardiovascular events, infections and malignancies were the most common causes of mortality.^{155;156}

Hypersensitivity reactions. In a study on more than 3000 patients with sc and almost 6000 patients with iv TCZ, there were approximately 1% hypersensitivity reactions, observed with both formulations (not injection site reactions); however, claims data suggest much more frequent hypersensitivity reactions with iv compared to sc application.¹⁵⁷ Of these, 20-40% were serious. The reactions were not related to the presence of anti-drug antibodies.¹⁵⁸ For sarilumab, which is only available in a sc formulation, 0.3% of patients had hypersensitivity reactions leading to treatment discontinuation.¹⁵⁹

Safety in pregnancy. Analyses of TCZ exposed pregnant women from the global safety database revealed that preterm birth (before week 37) occurred in about one-third of the prospectively reported pregnancies; elective termination of pregnancy was performed in 17.2% of pregnancies, 21.7% of pregnancies ended in spontaneous abortion.¹⁶⁰ These data are not different from observations with anti-TNF agents¹⁶¹ and may mostly be due to higher disease activity in patients on biologic agents; disease activity is a known risk factor for pre-term delivery. There is no increased risk of malformations and also no increased risk of adverse pregnancy outcomes for fathers exposed to IL-6R blockade.¹⁶⁰

RESEARCH AGENDA

As always when deriving consensus statement or recommendations, one finds many questions which have not been answered sufficiently in the literature. However, many questions have been

addressed and the respective information can be found in the SLR paper. Those questions that were posed in the first version of this statement but have not received satisfactory answers will be repeated here. Other questions arose in the course of the present deliberations.

1. Different drugs targeting the same molecule are approved for different diseases. Can one extrapolate from one anti-IL-6R inhibitor to another one regarding clinical efficacy and safety in the different indications?
2. Can one use anti-IL-6R blockers effectively and safely after one or more JAKinibs have failed?
3. What is the comparative efficacy of JAK-inhibitors and anti-IL-6 principles in monotherapy and combination therapy?
4. In the USA, an initial dose of 4mg/kg is recommended: what are the risks and benefits of this approach?
5. What is the efficacy and safety when IL-6 pathway inhibitors are given to patients previously treated with rituximab (with or without persistent B-cell depletion) or abatacept?
6. Are IL-6 inhibitors safe when used with or immediately after Jak inhibitors?
7. Does the use of isoniazid lead to significant increases in liver function tests in patients with IL-6 inhibitor mono- and combination therapy?
8. Is there a need to stop therapy with IL-6-blockers before fathering a child?
9. What is the molecular effect of IL-6R antibodies on target cells? Reverse signaling?

DISCUSSION

This update of a consensus statement compiled almost ten years ago¹⁷ covers a variety of novel developments. Firstly, additional IL-6R blockers have been licensed and are in clinical use for the approved indications: sarilumab and satralizumab. Secondly, new indications for IL-6R inhibition have been approved, such as giant cell arteritis, CAR-T CRS and NMOSD, and interstitial lung disease in systemic sclerosis patients, and while sarilumab is only approved for RA, satrilzumab only for NMOSD and siltuximab only for Castelman's disease, it can be assumed that all these agents have efficacy across the indication profile. Thirdly, expectations existing that IL-6 ligand inhibitors may become available around the middle of the last decade were not met when the development of sirukumab was stopped after several phase 3 trials had been completed; another monoclonal antibody to IL-6, olokizumab, is currently in late phase development and one will see if this molecule is approved. Fourthly, and most importantly, much more information on the long-term adverse event profile both from clinical trials and registries is available today than a decade ago, providing reassurance of the safety of IL-6R blockade.

This update like the original version is primarily based on evidence from clinical trials and, therefore, most of the items have a high level of evidence and grade of recommendation. Only a few points are based on low evidence levels or expert opinion. Those with low evidence need to be clarified by further research.

The research agenda included in the first version of this consensus document was long and several questions raised then have been answered by new data. Other questions have still not been answered. Rather than repeating those, we have provided a new research agenda in the current statement.

This consensus statement, like others, has been developed to provide guidance to rheumatologists and other experts, but also patients and administrators, on what the task force regards as state-of-the-art in the context of managing patients with the use of drugs blocking IL-6. The individual points presented in Table 1 constitute a summary of the discussions and the text in the Results section should be considered as an integral part of these recommendations. The task force did not include JAKinibs, since (i) a consensus statement on the use of these agents was published recently² and (ii) JAKinibs inhibit not only signal transduction of IL-6, but also interferons and other cytokines; consequently, JAKinibs have a different indication profile and other safety issues may be relevant.

In summary, blocking the IL-6R is a major therapeutic advance for many diseases in adulthood and children. We have summarized the current state of these agents in terms of efficacy and safety has been summarized which has significantly advanced since the time of the first version of this consensus statement. Future research will provide even more insights and allow further expansion of these drugs' profile for the benefit of patients in a large spectrum of inflammatory diseases.

Table 1. IL-6 pathway blocking agents and their targets

Table 2. Consensus Statements on the use of IL-6 blocking agents.

Reference List

- (1) Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet* 2016; 388(10055):2023-2038.
- (2) Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleischmann RM, Geissler K et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. *Ann Rheum Dis* 2021; 80(1):71-87.

- (3) Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet* 2004; 364:263-269.
- (4) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van SD et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. *Ann Rheum Dis* 2010; 69(1):65-69.
- (5) Verschueren P, De CD, Corluy L, Joos R, Langenaken C, Taelman V et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. *Ann Rheum Dis* 2015; 74(1):27-34.
- (6) Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). *Ann Rheum Dis* 2014; 73(1):75-85.
- (7) Verstappen SMM, Jacobs JW, van der Venn MJ, Heurkens AHM, Schenk Y, ter Borg EJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis* 2007; 66(11):1443-1449.
- (8) Gullick NJ, Oakley SP, Zain A, Gibson T, Jones T, Mistlin A et al. Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years. *Rheumatology (Oxford)* 2012; 51(4):759-761.
- (9) van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Booma-Frankfort C, van der Veen MJ et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. *Ann Intern Med* 1996; 124(8):699-707.
- (10) Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis* 2016; 75(1):3-15.
- (11) Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol* 2016; 68(1):1-26.
- (12) Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis* 2020; 79(6):685-699.
- (13) Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM et al. APLAR rheumatoid arthritis treatment recommendations. *Int J Rheum Dis* 2015; 18(7):685-713.
- (14) Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR et al. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. *Ann Rheum Dis* 2000; 59:504-505.
- (15) Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Ann Rheum Dis* 2013; 72 Suppl 2:ii2-34.

- (16) Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. *Ann Rheum Dis* 2011; 70(6):909-920.
- (17) Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. *Ann Rheum Dis* 2013; 72:482-492.
- (18) Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. *J Rheumatol* 24, 518-523. 1997.

Ref Type: Journal (Full)

- (19) Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 1999; 340(6):448-454.
- (20) Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. *Arthritis Res* 2002; 4 Suppl 3:S233-S242.
- (21) Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. *Immunity* 2019; 50(4):1007-1023.
- (22) O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. *Science* 2010; 327(5969):1098-1102.
- (23) Kishimoto T. IL-6: from its discovery to clinical applications. *Int Immunol* 2010; 22(5):347-352.
- (24) Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. *Nat Rev Drug Discov* 2012; 11(3):234-250.
- (25) Cronstein BN. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis. *Bull NYU Hosp Jt Dis* 2007; 65 Suppl 1:S11-S15.
- (26) Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. *J Hepatol* 2016; 64(6):1403-1415.
- (27) Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. *J Leukoc Biol* 2006; 80(2):227-236.
- (28) Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. *Nat Immunol* 2017; 18(1):74-85.
- (29) Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. *J Rheumatol* 1993; 20(2):259-262.
- (30) Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol* 2015; 16(5):448-457.

- (31) Van RM, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody(R) ALX-0061 supports its clinical development in rheumatoid arthritis. *Arthritis Res Ther* 2015; 17:135.
- (32) Lacroix M, Rousseau F, Guilhot F, Malinge P, Magistrelli G, Herren S et al. Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex. *J Biol Chem* 2015; 290(45):26943-26953.
- (33) Paonessa G, Graziani R, De SA, Savino R, Ciapponi L, Lahm A et al. Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. *EMBO J* 1995; 14(9):1942-1951.
- (34) U.S. Food and Drug Administration - Center for Drug Evaluation and Research. Pharmacology/Toxicology Review and Evaluation - Sylvant (Siltuximab). *chrome-extension://efaidnbnmnibpcjpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F2014%2F125496Orig1s000PharmR.pdf&clen=7170151&chunk=true (last accessed January 3, 2022)* 2014.
- (35) Creative Biolabs. Human Anti-IL6 Recombinant Antibody (clone EBI-029). <https://www.creativebiolabs.net/anti-il6-recombinant-antibody-clone-ebi-029-104271.htm> (last accessed November 25, 2021) 2021.
- (36) van der Heijde D, Aletaha D, Carmona L, Edwards CJ, Kvien TK, Kouloumas M et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. *Ann Rheum Dis* 2015; 74(1):8-13.
- (37) Oxford Center for Evidence Based Medicine. Levels of Evidence. 2009.
Ref Type: Online Source
- (38) Kastrati K, et al. SLR for updated IL-6 consensus statement. *submitted to RMD Open* 2021.
- (39) Gabay C, Emery P, van VR, Dikranian A, Alten R, Pavelka K et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet* 2013; 381(9877):1541-1550.
- (40) Burmester GR, Lin Y, Patel R, van AJ, Mangan EK, Graham NM et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis* 2017; 76(5):840-847.
- (41) Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 2017; 76(6):1113-1136.
- (42) Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van VR et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis* 2020; 79(6):744-759.
- (43) Hetland ML, Haavardsholm EA, Rudin A, Nordstrom D, Nurmohamed M, Gudbjornsson B et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. *BMJ* 2020; 371:m4328.

- (44) Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellesse F et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. *Lancet* 2021; 397(10271):305-317.
- (45) Pappas DA, St JG, Etzel CJ, Fiore S, Blachley T, Kimura T et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. *Ann Rheum Dis* 2021; 80(1):96-102.
- (46) Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. *BMJ* 2019; 364:l67.
- (47) Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. *Ann Rheum Dis* 2014; 73(5):803-809.
- (48) Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. *Ann Rheum Dis* 2015; 75:1081-1091.
- (49) Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). *Ann Rheum Dis* 2016; 75(11):1917-1923.
- (50) Teitsma XM, Marijnissen AK, Bijlsma JW, Lafeber FP, Jacobs JW. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. *Arthritis Res Ther* 2016; 18(1):211.
- (51) Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. *N Engl J Med* 2016; 374(13):1243-1252.
- (52) Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, GC et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995; 38:727-735.
- (53) Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. *Ann Rheum Dis* 2007; 66 Suppl 3:iii56-iii60.
- (54) Aletaha D, Smolen JS. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. *Nat Rev Rheumatol* 2019; 15(11):633-634.
- (55) Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. *Arthritis Res* 2005; 7:R796-R806.
- (56) Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. *Ann Rheum Dis* 2015; 74(6):1110-1117.

- (57) Brunner HI, Ruperto N, Zuber Z, Cuttica R, Keltsev V, Xavier RM et al. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. *Arthritis Rheumatol* 2021; 73(3):530-541.
- (58) Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. *Rheumatology (Oxford)* 2021; 60(10):4568-4580.
- (59) Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. *Lancet* 2008; 371(9617):998-1006.
- (60) De BF, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. *N Engl J Med* 2012; 367(25):2385-2395.
- (61) Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H et al. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. *Ann Rheum Dis* 2018; 77(12):1720-1729.
- (62) Chugai Pharmaceutical Company J. Adult onset Still's disease. *Press Release* 2019; https://www.chugai-pharm.co.jp/english/news/detail/20190522160000_618.html (last accessed November 13, 2021).
- (63) Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D et al. Trial of Tocilizumab in Giant-Cell Arteritis. *N Engl J Med* 2017; 377(4):317-328.
- (64) Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. *Cochrane Database Syst Rev* 2021; 8:CD013484.
- (65) Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). *Ann Rheum Dis* 2018; 77(3):348-354.
- (66) Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med* 2014; 371(16):1507-1517.
- (67) Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. *Oncologist* 2018; 23(8):943-947.
- (68) Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. *Blood* 2005; 106(8):2627-2632.
- (69) van RF, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2014; 15(9):966-974.
- (70) Sarosiek S, Shah R, Munshi NC. Review of siltuximab in the treatment of multicentric Castleman's disease. *Ther Adv Hematol* 2016; 7(6):360-366.

- (71) Carnero CE, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. *J Neuroinflammation* 2021; 18(1):208.
- (72) Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. *N Engl J Med* 2019; 381(22):2114-2124.
- (73) Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. *Lancet Neurol* 2020; 19(5):402-412.
- (74) Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review. *Semin Arthritis Rheum* 2020; 50(3):521-525.
- (75) Spiera R, Unizony SH, Bao M, Luder Y, Han J, Pavlov A et al. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. *Semin Arthritis Rheum* 2021; 51(2):469-476.
- (76) Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP et al. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. *Arthritis Rheumatol* 2021; 73(7):1301-1310.
- (77) Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med* 2020; 8(10):963-974.
- (78) Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. *Ann Rheum Dis* 2014; 73(1):95-100.
- (79) Sieper J, Inman RD, Badalamenti S, Radin A, Braun J. Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized, double-blind, placebo-controlled, international study (ALIGN). *Ann Rheum Dis* 71 (Suppl 3), 111. 2012.

Ref Type: Abstract

- (80) Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R et al. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. *Arthritis Rheumatol* 2016; 68(9):2163-2173.
- (81) Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. *Arthritis Rheum* 2010; 62(2):542-552.
- (82) Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. *Ann Rheum Dis* 2017; 76(3):534-542.
- (83) Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020; 26(10):1636-1643.

- (84) Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. *Ann Rheum Dis* 2020; 79(9):1143-1151.
- (85) Malgie J, Schoones JW, Zeegers MP, Pijls BG. Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysis. *Sci Rep* 2021; 11(1):21522.
- (86) Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J Med* 2021; 384(16):1491-1502.
- (87) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021; 397(10285):1637-1645.
- (88) World Health Organization. WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access. <https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access> (last accessed January 3, 2022) 2021.
- (89) U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19> (last accessed January 3, 2022) 2021.
- (90) European Medicines Agency. EMA recommends approval for use of RoActemra in adults with severe COVID-19. <https://www.ema.europa.eu/en/news/ema-recommends-approval-use-roactemra-adults-severe-covid-19> (last accessed January 3, 2022) 2021.
- (91) Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. *J Rheumatol* 2013; 40(7):1074-1081.
- (92) Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. *Mod Rheumatol* 2014; 24(1):17-25.
- (93) Shafran IH, Alasti F, Smolen JS, Aletaha D. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. *Ann Rheum Dis* 2020; 79(7):874-882.
- (94) Boyapati A, Schwartzman S, Mshid J, Choy E, Genovese MC, Burmester GR et al. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. *Arthritis Rheumatol* 2020; 72(9):1456-1466.
- (95) Gardette A, Ottaviani S, Sellam J, Berenbaum F, Liote F, Meyer A et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. *Clin Rheumatol* 2016; 35(4):857-861.

- (96) Davies R, Vivekanantham A, Lunt M, Watson K, Hyrich K, Bluett J. The effect of bodyweight on response to intravenous or subcutaneous tocilizumab in patients with rheumatoid arthritis. *Ann Rheum Dis* 2020; 79 (suppl 1):981.
- (97) Schafer M, Albrecht K, Kekow J, Rockwitz K, Liebhaber A, Zink A et al. Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT. *RMD Open* 2020; 6(3).
- (98) Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Ann Rheum Dis* 2011; 70(3):404-413.
- (99) Forsblad-d'Elia H, Bengtsson K, Kristensen LE, Jacobsson LT. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. *Rheumatology (Oxford)* 2015; 54(7):1186-1193.
- (100) Saraux A, Barnetche T, Baudens G, Idier I, Delaporte F, Hilliquin P. Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months. *Ann Rheum Dis* 2019; 78 (suupl 2):A725.
- (101) Best JH, Vlad SC, Tominna L, Abbass I. Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic. *Rheumatol Ther* 2020; 7(2):345-355.
- (102) Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S et al. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. *Arthritis Res Ther* 2018; 20(1):129.
- (103) Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D et al. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. *RMD Open* 2017; 3(1):e000416.
- (104) Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R et al. Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. *RMD Open* 2018; 4(1):e000602.
- (105) Ayaz NA, Karadag SG, Koc R, Demirkan FG, Cakmak F, Sonmez HE. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study. *Rheumatol Int* 2020; 40(7):1111-1116.
- (106) Del Rinco I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. *Arthritis Rheumatol* 2014; 66(2):264-272.
- (107) Ocon AJ, Reed G, Pappas DA, Curtis JR, Kremer JM. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. *Ann Rheum Dis* 2021; 80(12):1522-1529.
- (108) Burmester GR, Buttgereit F, Bernasconi C, Alvaro-Gracia JM, Castro N, Dougados M et al. Continuing versus tapering glucocorticoids after achievement of low disease activity or

remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. *Lancet* 2020; 396(10246):267-276.

- (109) Wilson JC, Sarsour K, Collinson N, Tuckwell K, Musselman D, Klearman M et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. *Semin Arthritis Rheum* 2017; 46(6):819-827.
- (110) Johnston SS, McMorrow D, Farr AM, Juneau P, Ogale S. Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic. *Drugs Real World Outcomes* 2015; 2(1):99-109.
- (111) Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. *J Med Econ* 2012; 15(2):340-351.
- (112) Verhoeven MMA, Tekstra J, Jacobs JWJ, Bijlsma JWJ, van Laar JM, Petho-Schramm A et al. Is tocilizumab monotherapy as effective in preventing radiographic progression in rheumatoid arthritis as its combination with methotrexate? *Arthritis Care Res (Hoboken)* 2020.
- (113) Muszbek N, Proudfoot C, Fournier M, Chen CI, Kuznik A, Kiss Z et al. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. *Adv Ther* 2019; 36(6):1337-1357.
- (114) European Medicines Agency. RoActemra-Summary of product characteristics. [Last accessed April 29th, 2012]. 2009.

Ref Type: Grant

- (115) Crnkic KM, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. *Arthritis Res Ther* 2013; 15(1):R1.
- (116) Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. *Ann Rheum Dis* 2013; 72(8):1362-1366.
- (117) Bingham CO, III, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). *Ann Rheum Dis* 2015; 74(5):818-822.
- (118) Tsuru T, Terao K, Murakami M, Matsutani T, Suzaki M, Amamoto T et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. *Mod Rheumatol* 2014; 24(3):511-516.
- (119) Bugatti S, De SL, Balduzzi S, Greco MI, Luvaro T, Cassaniti I et al. Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. *Ann Rheum Dis* 2021; 80(12):1635-1638.
- (120) Mrak D, Tobudic S, Koblichke M, Graninger M, Radner H, Sieghart D et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. *Ann Rheum Dis* 2021; 80(10):1345-1350.

- (121) Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F et al. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. *Ann Rheum Dis* 2021.
- (122) Shinoki T, Hara R, Kaneko U, Miyamae T, Imagawa T, Mori M et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. *Mod Rheumatol* 2012; 22(6):871-876.
- (123) Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. *Rheumatology (Oxford)* 2018; 57(6):997-1001.
- (124) Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. *Ann Rheum Dis* 2019; 78(4):456-464.
- (125) Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. *Ann Rheum Dis* 2018; 77(6):905-910.
- (126) Gron KL, Arkema EV, Glinborg B, Mehnert F, Ostergaard M, Dreyer L et al. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. *Ann Rheum Dis* 2019; 78(3):320-327.
- (127) Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. *Ann Rheum Dis* 2016; 75(10):1843-1847.
- (128) Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. *Rheumatology (Oxford)* 2014; 53(10):1872-1885.
- (129) Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. *Ann Rheum Dis* 2011; 70(12):2148-2151.
- (130) Wadstrom H, Frisell T, Askling J. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. *JAMA Intern Med* 2017; 177(11):1605-1612.
- (131) Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. *Mod Rheumatol* 2016; 26(5):642-650.
- (132) Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, Kelman A et al. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. *Arthritis Rheumatol* 2017; 69(9):1751-1761.

- (133) McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. *Ann Rheum Dis* 2015; 74(4):694-702.
- (134) Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. *Ann Rheum Dis* 2016; 75(10):1806-1812.
- (135) Paul SK, Montvida O, Best JH, Gale S, Pethoe-Schramm A, Sarsour K. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. *Semin Arthritis Rheum* 2018; 47(4):478-484.
- (136) Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. *Rheumatology (Oxford)* 2017; 56(4):541-549.
- (137) Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab. *J Rheumatol* 2015; 42(4):712-722.
- (138) Klein A, Klotsche J, Hugle B, Minden K, Hospach A, Weller-Heinemann F et al. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. *Rheumatology (Oxford)* 2020; 59(9):2287-2298.
- (139) Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C et al. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. *Arthritis Rheumatol* 2020; 72(1):31-40.
- (140) Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. *Semin Arthritis Rheum* 2018; 48(3):399-405.
- (141) Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K et al. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. *Arthritis Rheumatol* 2017; 69(6):1154-1164.
- (142) Xie F, Yun H, Levitan EB, Muntner P, Curtis JR. Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. *Arthritis Care Res (Hoboken)* 2019; 71(8):1004-1018.
- (143) Chen SK, Lee H, Jin Y, Liu J, Kim SC. Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus. *Rheumatol Adv Pract* 2020; 4(2):rkaa027.
- (144) Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, John GS et al. Interleukin-6 receptor blockade or TNFalpha inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. *Arthritis Res Ther* 2020; 22(1):206.
- (145) Mori S, Yoshitama T, Hidaka T, Hirakata N, Ueki Y. Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study). *Ann Rheum Dis* 2015; 74(3):627-630.

- (146) Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study. *Arthritis Res Ther* 2015; 17:319.
- (147) Strangfeld A, Meissner Y, Schäfer, Baganz L, Schneider M, Wilden E et al. *No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab*. *Arthritis Rheumatol* 2019; 71 (S10):2306-2308.
- (148) Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. *Lancet Neurol* 2020; 19(5):391-401.
- (149) Shin A, Park EH, Dong YH, Ha YJ, Lee YJ, Lee EB et al. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study. *Osteoporos Int* 2020; 31(11):2131-2139.
- (150) Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, Hatta K et al. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. *Rheumatology (Oxford)* 2014; 53(5):900-903.
- (151) Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, Chao WC et al. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. *PLoS One* 2017; 12(11):e0188454.
- (152) Fleischmann R, Genovese MC, Maslova K, Leher H, Praestgaard A, Burmester GR. Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. *Rheumatology (Oxford)* 2021; 60(11):4991-5001.
- (153) Aletaha D, Bingham CO, III, Tanaka Y, Agarwal P, Kurrasch R, Tak PP et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. *Lancet* 2017; 389(10075):1206-1217.
- (154) Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R et al. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. *Ann Rheum Dis* 2017; 76(12):2001-2008.
- (155) Thorne C, Takeuchi T, Karpouzas GA, Sheng S, Kurrasch R, Fei K et al. Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study. *RMD Open* 2018; 4(2):e000731.
- (156) Aletaha D, Bingham CO, Karpouzas GA, Takeuchi T, Thorne C, Bili A et al. Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). *RMD Open* 2021; 7(1).
- (157) Yun H, Xie F, Beyl RN, Chen L, Lewis JD, Saag KG et al. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2017; 69(10):1526-1534.
- (158) Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. *Ann Rheum Dis* 2017; 76(6):1078-1085.
- (159) Food and Drug Administration U. Prescribing information for Kevzara (Sailumab). *chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/viewer*

html?pdfurl=https%3A%2F%2Fproducts.sanofi.us%2Fkevozara%2Fkevozara.pdf&clen=126400&chunk=true (last accessed November 25, 2011) 2018.

- (160) Hoeltzenbein M, Beck E, Rajwanshi R, Gotestam SC, Berber E, Schaefer C et al. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data. *Semin Arthritis Rheum* 2016; 46(2):238-245.
- (161) Broms G, Kieler H, Ekblom A, Gissler M, Hellgren K, Lahesmaa-Korpinen AM et al. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. *Pharmacoepidemiol Drug Saf* 2020; 29(3):316-327.

Table 1. Molecules that interfere with the IL-6 pathway. Mab, monoclonal antibody; sgp, soluble glycoprotein; Fc, IgG-Fc fragment; other abbreviations see text.

Biological agent	Molecular type	Target	Approval for
Tocilizumab	Humanized MAb	IL-6R	RA, JIA, sJIA, GCA, others
Sarilumab	Human MAb	IL-6R	RA
Satralizumab	Humanized MAb	IL-6R	NMOSD
Siltuximab	Chimeric MAb	IL-6, site 1	Castleman's disease
Sirukumab	Human MAb	IL-6, site 1	N.a.
Clazakizumab	Humanized MAb	IL-6, site 1	N.a.
Olokizumab	Humanized MAb	IL-6, site 3	N.a.
EBI-028	scFv fragment	IL-6, site 2	N.a.
Olamkizept	sgp130-Fc	IL-6-sIL-6R complex	N.a.
JAK 1,3-inhibitors	Small chemical	IL-6R signaling	RA, PsA, AS, PsO, others

Table 2. Consensus statements with levels and grades of evidence, levels of agreement and last voting results

Statement	Level of Agreement (0-10)	Last voting results
INDICATION - <u>Rheumatoid arthritis</u> (Level 1a, Grade A)		
<p>Population: Active RA (at least moderate disease activity according to a validated composite measure) characterized by an inadequate response to (or intolerance of)</p> <ul style="list-style-type: none"> - at least one conventional synthetic disease modifying antirheumatic drug (csDMARDs) or - a biological DMARD (bDMARD) or - a targeted synthetic (ts) DMARD (JAK-inhibitor) 	9.8±0.5	100%
<p>Dosing scheme:</p> <ul style="list-style-type: none"> - SAR: 200mg s.c. every 2 weeks (Level 1a, Grade A) - TCZ: 162mg s.c. weekly or 8 mg/kg every 4 weeks as intravenous infusion, usually over 1 h (Level 1a, Grade A) - SAR/TCZ should be used in combination with methotrexate (MTX) (alternatively in combination with other csDMARDs) or, if MTX or another csDMARD is inappropriate, as monotherapy. (Level 1a, Grade A) 	9.9±0.3	100%
<p>Dose reduction:</p> <ul style="list-style-type: none"> - As a shared decision between patients and their rheumatologist - Indication: <ul style="list-style-type: none"> o occurrence of certain adverse events; 	9.5±0.8	91%

<ul style="list-style-type: none"> ○ in patients with sustained remission, after having tapered GC; discontinuation of concomitant csDMARDs (especially MTX) can also be considered. - Scheme: SAR from 200 to 150mg or TCZ from 8 to 4 mg/kg, or interval increase. 		
INDICATION - <u>Polyarticular-course juvenile idiopathic arthritis</u> (Level 1b, Grade A)		
Population: Active pcJIA (≥ 5 active joints, ≥ 3 with limitation of motion), characterized by an inadequate response to MTX.	9.6±0.8	94%
Dosing (TCZ): <ul style="list-style-type: none"> - IV dosing every four weeks: 8mg/kg for weight ≥30kg; 8-10mg/kg for weight <30kg - SC dosing: ≥30kg: 162 s.c. / 2 weeks; <30kg: 162mg s.c. / 3 weeks - In combination with MTX (unless not tolerated) 	9.9±0.3	94%
INDICATION - <u>Systemic juvenile idiopathic arthritis</u> (Level 1b, Grade A)		
Population: Active sJIA, refractory to NSAIDs and GC	9.8±0.5	94%
Dosing (TCZ): <ul style="list-style-type: none"> - IV dosing every two weeks: 8mg/kg for weight ≥30kg; 12mg/kg for weight <30kg - SC dosing: ≥30kg: 162mg s.c. / week; <30kg: 162mg s.c. / 2 weeks - Use as monotherapy 	9.9±0.3	94%
INDICATION - <u>Giant cell arteritis</u> (Level 1b, Grade A)		
Population: New onset or relapsing GCA, especially those at high risk of GC related AE	9.7±0.7	90%
Dosing (TCZ): <ul style="list-style-type: none"> - 162mg s.c. weekly - always start in combination with GCs, but alongside GC tapering 	9.7±0.7	90%
INDICATION - <u>Takayasu Arteritis</u> (Level 2a, Grade B)		
Population: Patients aged ≥12 years with relapsing and refractory to GC TAK	9.6±1.0	93%
Dosing (TCZ, only in Japan): <ul style="list-style-type: none"> - 162mg s.c. weekly - In combination with GCs, but alongside GC tapering 	9.7±0.7	93%
INDICATION - <u>Adult-onset Still's disease</u> (Level 1b, Grade A)		
Population: <ul style="list-style-type: none"> - AoSD refractory to GC 	9.5±0.8	93%93%
Dosing (TCZ, only in Japan): <ul style="list-style-type: none"> - only IV dosing at 8mg/kg every 2 weeks 	9.5±0.9	
INDICATION - <u>Castleman's disease</u> (Level 2b/1b, Grade B)		
Population:	9.8±0.6	93%

Human herpesvirus-8-seronegative patients with symptomatic multicentric Castleman's disease		
Dosing (TCZ in Japan, and Siltuximab in EU and USA): <ul style="list-style-type: none"> - TCZ: IV dosing: 8mg/kg every 2 weeks; SC dosing: 162mg weekly (Level 2b, Grade B) - Siltuximab: IV dosing: 11mg/kg every 3 weeks (Level 1b, Grade B) 	9.7±0.6	93%
INDICATION - <u>CAR-T-Cell induced Cytokine Release Syndrome (Level 2c, Grade B)</u>		
Population: Severe or life-threatening grades of CRS in adults and pediatric patients ≥ 2 years of age	9.7±0.6	93%
Dosing: IV TCZ dosing: once 8 mg/kg (12 mg/kg for pts <30 kg)	9.7±0.6	93%
INDICATION – <u>Neuromyelitis optica spectrum disorder NMOSD (Level 1b, Grade A)</u>		
Population: AQP4-IgG seropositive or seronegative relapsing NMOSD	9.7±0.5	93%
Dosing (Satralizumab in USA and Japan, in USA only seropositive adults): <ul style="list-style-type: none"> - Satralizumab: SC dosing: 120 mg at weeks 0, 2, and 4 and every 4 weeks as monotherapy or as combination therapy with immunosuppressant 	9.7±0.5	93%
DISEASE MANAGEMENT		
<ul style="list-style-type: none"> - Follow-up of clinical response: outcome measures which do not include acute phase reactants should be used to evaluate disease activity. - Risk of delaying diagnosis of infection because of APR normalization by IL-6R 	9.8±0.6	100%
PRE-TREATMENT SCREENING (Level 5, Grade D)		
<ul style="list-style-type: none"> - History and physical examination <ul style="list-style-type: none"> o Consider possible contraindications o Consider radiograph of the chest o Assess history of infections (especially history of hepatitis?), diverticulitis, any history of GI perforations (including peptic ulcer?) and malignancies - Routine laboratory testing, including lipid levels - Testing for hepatitis B and hepatitis C viral infections (persistence of HbsAg, anti-HBc) – - Screening for Tb - Assess necessity of vaccination; vaccination should be updated according to local recommendations; 	9.4±1.0	94%
CONTRAINDICATIONS (Level 5, Grade D)		
<ul style="list-style-type: none"> ▶ Allergy to IL6 inhibiting drug ▶ Clinically relevant co-morbidities, particularly active infections, diverticulitis 	9.6±0.7	94%
SAFETY (Level 2b, Grade B)		

<ul style="list-style-type: none"> - Serious bacterial infections and opportunistic infections occurred about twice as frequently with TCZ compared to placebo population (similar to other bDMARDs) <ul style="list-style-type: none"> o Risk of delaying diagnosis of infection because of APR normalization by IL-6R - Hepatic transaminase elevations - Gastrointestinal perforations, risk factors include a history of diverticulitis or GI ulcers, older age, GC and/or NSAID intake, no reported cases in children. - Neutropenia and rarely thrombocytopenia - Infusion reactions (~7%) <ul style="list-style-type: none"> o Severe infusion (hypersensitivity) reactions may occur but are rare (0.3%); they are more frequent with the 4 mg/kg than the 8 mg/kg dose iv / 162mg dose sc - Children with sJIA: possible risk for development of macrophage activation syndrome 	9.6±0.9	94%
--	----------------	------------